ADReCS

Pharmaceutical Information

Drug Name	Sulfasalazine
Drug ID	BADD_D02093
Description	A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage	For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status	approved
ATC Code	A07EC01
DrugBank ID	DB00795
KEGG ID	D00448
MeSH ID	D012460
PubChem ID	5339
TTD Drug ID	D02ZTJ
NDC Product Code	63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII	3XC8GUZ6CB
Synonyms	Sulfasalazine \| Salicylazosulfapyridine \| Sulphasalazine \| Salazosulfapyridine \| Pyralin EN \| Azulfadine \| Azulfidine EN \| Azulfidine \| Asulfidine \| Colo-Pleon \| Colo Pleon \| Pleon \| Ulcol \| Sulfasalazin medac \| Sulfasalazin-Heyl \| Sulfasalazin Heyl \| Sulfasalazine FNA \| Ucine \| Salazopyrin \| ratio-Sulfasalazine \| ratio Sulfasalazine

Chemical Information

Molecular Formula	C18H14N4O5S
CAS Registry Number	599-79-1
SMILES	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Drug reaction with eosinophilia and systemic symptoms	12.03.01.064; 23.03.05.005; 10.01.01.021	0.016124%		Not Available
Mouth swelling	23.04.01.020; 10.01.05.020; 07.05.04.007	0.000303%		Not Available
Anal incontinence	17.05.01.021; 07.01.06.029	0.000303%
Liver function test increased	13.03.04.031	-	-	Not Available
Alopecia universalis	23.02.02.010	0.000303%		Not Available
Anaemia folate deficiency	01.03.01.005; 14.12.02.009	0.000606%		Not Available
Breast cancer stage II	21.05.01.019; 16.10.01.011	0.000303%		Not Available
Dermatitis exfoliative generalised	23.03.07.002; 10.01.01.029	0.000303%		Not Available
Hilar lymphadenopathy	01.09.01.023; 22.09.03.005	0.000303%		Not Available
Rectal stenosis	07.13.05.003	0.000303%
Anti-neutrophil cytoplasmic antibody positive vasculitis	24.12.04.002; 10.02.02.023	0.000455%		Not Available
Multi-organ disorder	08.01.03.074	-	-	Not Available
Foot deformity	15.10.03.005	-	-	Not Available
Spinal pain	15.02.01.008; 08.01.08.030; 17.10.01.020	0.000303%		Not Available
Internal haemorrhage	24.07.01.072	0.000455%		Not Available
Pseudomyopia	06.02.04.011	0.000303%		Not Available
Drug effect less than expected	08.06.01.036	-	-	Not Available
Drug ineffective for unapproved indication	12.09.02.002; 08.06.01.038	0.006850%		Not Available
Haemophagocytic lymphohistiocytosis	16.32.03.038; 10.02.01.077; 01.05.01.026	0.001667%		Not Available
Hypersensitivity myocarditis	10.01.03.055; 02.04.03.006	-	-	Not Available
Hypersensitivity pneumonitis	22.01.01.027; 10.01.03.056	0.000303%		Not Available
Idiopathic intracranial hypertension	17.07.02.011	0.000455%		Not Available
Illness	08.01.03.091	0.000909%		Not Available
Myelosuppression	01.03.03.015	0.000455%		Not Available
Potentiating drug interaction	08.06.03.015	0.000303%		Not Available
Severe cutaneous adverse reaction	12.03.01.070; 11.07.01.031; 10.01.01.044; 23.03.05.011	0.000303%		Not Available
Spinal stenosis	17.10.01.031; 15.10.04.014	0.000303%		Not Available
Therapeutic product effect decreased	08.06.01.050	0.002364%		Not Available
Therapeutic product effect delayed	08.06.01.051	-	-	Not Available
Therapeutic product effect incomplete	08.06.01.052	0.020943%		Not Available

The 14th Page First Pre 14 15 Next Last Total 15 Pages